CELLINK publishes annual report for 2017/2018

CELLINKs' annual report is now available on http://cellink.com/investor-relations. A physical copy can be requested through ir@cellink.com. An English digital copy will be available at CELLINKs' website before the annual general meeting.

For further information, please contact:

Erik Gatenholm, CEO                                                     Gusten Danielsson, CFO

Phone: +46 73 267 00 00                                               Phone: +46 70 991 86 04

E-mail: eg@cellink.com                                                E-mail: gd@cellink.com

About CELLINK

CELLINK has created one of the world's first universal Bioinks, today used by many of the world's most well-reputed research institutions. A Bioink can be mixed with living cells to print functional human tissues and if future research is successful, eventually, complete human organs in so-called 3D-Bioprinters. CELLINK's universal Bioink shows excellent results and can be used in both CELLINK's proprietary 3D Bioprinters and in 3D Bioprinters developed by other operators. CELLINK is listed at Nasdaq First North with the ticker CLNK. Erik Penser Bank AB, tel: +46 8 463 80 00, is the Company's Certified Adviser.